Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | CA12 | O43570 | 1/20 | 0.73 |
| ▸ | CA1 | P00915 | 1/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.73 |
| ▸ | CA4 | P22748 | 1/20 | 0.73 |
| ▸ | CA6 | P23280 | 1/20 | 0.73 |
| ▸ | CA7 | P43166 | 1/20 | 0.73 |
| ▸ | TPMT | P51580 | 1/20 | 0.73 |
| ▸ | CA9 | Q16790 | 1/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29618985 | 1.00 | TSHR (0.76) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL31327211 | 0.90 | CES2 (0.67) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL13082597 | 0.90 | TSHR (0.63) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL17077317 | 0.90 | MAPT (0.69) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL339242 | 0.90 | CA12 (0.71) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL12695696 | 0.89 | TSHR (0.61) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL11347666 | 0.89 | CES2 (0.65) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL27468173 | 0.88 | CA12 (0.69) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL13890438 | 0.88 | TSHR (0.66) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL1493250 | 0.86 | CYP1A2 (1.00) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119143591-A | Benzyl benzoyl or fluoro alkane substituted phenol compound and synthetic method and application thereof | 河北中医药大学 | 2024-12-17 | — | — | CN | claimed |
| CN-119143591-A | Benzyl benzoyl or fluoro alkane substituted phenol compound and synthetic method and application thereof | 河北中医药大学 | 2024-12-17 | — | — | CN | disclosed |
| US-9040647-B2 | Photochromic material | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2015-05-26 | — | — | US | disclosed |
| EP-2511307-B1 | PHOTOCHROMIC MATERIAL | MITSUBISHI GAS CHEMICAL CO (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-2511307-A1 | PHOTOCHROMIC MATERIAL | Mitsubishi Gas Chemical Company, Inc. (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120245317-A1 | PHOTOCHROMIC MATERIAL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2012-09-27 | — | — | US | disclosed |
| CN-102295548-A | Method for preparing di-(3,4-dimethoxy phenyl) ethyldione in ionic liquid | — | 2011-12-28 | — | — | CN | disclosed |
| CN-102295548-A | Method for preparing di-(3,4-dimethoxy phenyl) ethyldione in ionic liquid | — | 2011-12-28 | — | — | CN | disclosed |
| EP-2397468-A1 | NOVEL CROSSLINKED HEXAARYL BISIMIDAZOLE COMPOUND AND DERIVATIVE THEREOF, METHOD FOR PRODUCING THE COMPOUND AND PRECURSOR COMPOUND TO BE USED IN THE PRODUCTION METHOD | Abe, Jiro (JP) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397468-A1 | NOVEL CROSSLINKED HEXAARYL BISIMIDAZOLE COMPOUND AND DERIVATIVE THEREOF, METHOD FOR PRODUCING THE COMPOUND AND PRECURSOR COMPOUND TO BE USED IN THE PRODUCTION METHOD | Abe, Jiro (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20110306743-A1 | NOVEL CROSSLINKED HEXAARYL BISIMIDAZOLE COMPOUND AND DERIVATIVE THEREOF, METHOD FOR PRODUCING THE COMPOUND AND PRECURSOR COMPOUND TO BE USED IN THE PRODUCTION METHOD | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306743-A1 | NOVEL CROSSLINKED HEXAARYL BISIMIDAZOLE COMPOUND AND DERIVATIVE THEREOF, METHOD FOR PRODUCING THE COMPOUND AND PRECURSOR COMPOUND TO BE USED IN THE PRODUCTION METHOD | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2011-12-15 | — | — | US | disclosed |
| US-7842830-B2 | Transition-metal charge-transport materials, methods of fabrication thereof, and methods of use thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080121870-A1 | Transition-Metal Charge Transport Materials, Methods Of Fabrication Thereof, And Methods Of Use Thereof | GEORGIA TECH RESEACH CORPORATION | 2008-05-29 | — | — | US | disclosed |
| WO-2005123754-A2 | TRANSITION-METAL CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306743-A1 | NOVEL CROSSLINKED HEXAARYL BISIMIDAZOLE COMPOUND AND DERIVATIVE THEREOF, METHOD FOR PRODUCING THE COMPOUND AND PRECURSOR COMPOUND TO BE USED IN THE PRODUCTION METHOD | CDKL1, CDKL2, CDK4 | TSHR 2361/4885CYP2C9 400/4885CYP2C19 515/4885 |
| US-20080121870-A1 | Transition-Metal Charge Transport Materials, Methods Of Fabrication Thereof, And Methods Of Use Thereof | SLC39A3, SLC6A6, SLC6A9 | TSHR 4527/4885CYP2C9 3238/4885CYP2C19 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.